395 related articles for article (PubMed ID: 21904456)
1. Development of small interfering RNA delivery system using PEI-PEG-APRPG polymer for antiangiogenic vascular endothelial growth factor tumor-targeted therapy.
Lu ZX; Liu LT; Qi XR
Int J Nanomedicine; 2011; 6():1661-73. PubMed ID: 21904456
[TBL] [Abstract][Full Text] [Related]
2. Polyethylenimine/small interfering RNA-mediated knockdown of vascular endothelial growth factor in vivo exerts anti-tumor effects synergistically with Bevacizumab.
Höbel S; Koburger I; John M; Czubayko F; Hadwiger P; Vornlocher HP; Aigner A
J Gene Med; 2010 Mar; 12(3):287-300. PubMed ID: 20052738
[TBL] [Abstract][Full Text] [Related]
3. Advanced cancer therapy by integrative antitumor actions via systemic administration of miR-499.
Ando H; Asai T; Koide H; Okamoto A; Maeda N; Tomita K; Dewa T; Minamino T; Oku N
J Control Release; 2014 May; 181():32-9. PubMed ID: 24593893
[TBL] [Abstract][Full Text] [Related]
4. Soluble Flt-1 gene delivery using PEI-g-PEG-RGD conjugate for anti-angiogenesis.
Kim WJ; Yockman JW; Lee M; Jeong JH; Kim YH; Kim SW
J Control Release; 2005 Aug; 106(1-2):224-34. PubMed ID: 15970348
[TBL] [Abstract][Full Text] [Related]
5. Low-weight polyethylenimine cross-linked 2-hydroxypopyl-β-cyclodextrin and folic acid as an efficient and nontoxic siRNA carrier for gene silencing and tumor inhibition by VEGF siRNA.
Li JM; Wang YY; Zhang W; Su H; Ji LN; Mao ZW
Int J Nanomedicine; 2013; 8():2101-17. PubMed ID: 23766646
[TBL] [Abstract][Full Text] [Related]
6. Efficient and Tumor Targeted siRNA Delivery by Polyethylenimine-graft-polycaprolactone-block-poly(ethylene glycol)-folate (PEI-PCL-PEG-Fol).
Liu L; Zheng M; Librizzi D; Renette T; Merkel OM; Kissel T
Mol Pharm; 2016 Jan; 13(1):134-43. PubMed ID: 26641134
[TBL] [Abstract][Full Text] [Related]
7. Prostate cancer cell-specific VEGF siRNA delivery system using cell targeting peptide conjugated polyplexes.
Kim SH; Lee SH; Tian H; Chen X; Park TG
J Drug Target; 2009 May; 17(4):311-7. PubMed ID: 19242850
[TBL] [Abstract][Full Text] [Related]
8. Specific cell targeting with APRPG conjugated PEG-PLGA nanoparticles for treating ovarian cancer.
Wang Y; Liu P; Duan Y; Yin X; Wang Q; Liu X; Wang X; Zhou J; Wang W; Qiu L; Di W
Biomaterials; 2014 Jan; 35(3):983-92. PubMed ID: 24176193
[TBL] [Abstract][Full Text] [Related]
9. Effective delivery of an angiogenesis inhibitor by neovessel-targeted liposomes.
Katanasaka Y; Ida T; Asai T; Maeda N; Oku N
Int J Pharm; 2008 Aug; 360(1-2):219-24. PubMed ID: 18565703
[TBL] [Abstract][Full Text] [Related]
10. PEI-g-PEG-RGD/small interference RNA polyplex-mediated silencing of vascular endothelial growth factor receptor and its potential as an anti-angiogenic tumor therapeutic strategy.
Kim J; Kim SW; Kim WJ
Oligonucleotides; 2011; 21(2):101-7. PubMed ID: 21375397
[TBL] [Abstract][Full Text] [Related]
11. Smart polymeric nanoparticles with pH-responsive and PEG-detachable properties for co-delivering paclitaxel and survivin siRNA to enhance antitumor outcomes.
Jin M; Jin G; Kang L; Chen L; Gao Z; Huang W
Int J Nanomedicine; 2018; 13():2405-2426. PubMed ID: 29719390
[TBL] [Abstract][Full Text] [Related]
12. In vitro and in vivo evaluation of APRPG-modified angiogenic vessel targeting micelles for anticancer therapy.
Guo P; Song S; Li Z; Tian Y; Zheng J; Yang X; Pan W
Int J Pharm; 2015; 486(1-2):356-66. PubMed ID: 25840274
[TBL] [Abstract][Full Text] [Related]
13. Local and systemic delivery of VEGF siRNA using polyelectrolyte complex micelles for effective treatment of cancer.
Kim SH; Jeong JH; Lee SH; Kim SW; Park TG
J Control Release; 2008 Jul; 129(2):107-16. PubMed ID: 18486981
[TBL] [Abstract][Full Text] [Related]
14. The investigation of polymer-siRNA nanoparticle for gene therapy of gastric cancer in vitro.
Wu Y; Wang W; Chen Y; Huang K; Shuai X; Chen Q; Li X; Lian G
Int J Nanomedicine; 2010 Mar; 5():129-36. PubMed ID: 20309399
[TBL] [Abstract][Full Text] [Related]
15. PEG conjugated VEGF siRNA for anti-angiogenic gene therapy.
Kim SH; Jeong JH; Lee SH; Kim SW; Park TG
J Control Release; 2006 Nov; 116(2):123-9. PubMed ID: 16831481
[TBL] [Abstract][Full Text] [Related]
16.
Wan X; Sun R; Bao Y; Zhang C; Wu Y; Gong Y
Mol Pharm; 2021 Nov; 18(11):3990-3998. PubMed ID: 34591491
[TBL] [Abstract][Full Text] [Related]
17. In Vivo Antitumor Activity of Folate-Conjugated Cholic Acid-Polyethylenimine Micelles for the Codelivery of Doxorubicin and siRNA to Colorectal Adenocarcinomas.
Amjad MW; Amin MC; Katas H; Butt AM; Kesharwani P; Iyer AK
Mol Pharm; 2015 Dec; 12(12):4247-58. PubMed ID: 26567518
[TBL] [Abstract][Full Text] [Related]
18. Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle.
Schiffelers RM; Ansari A; Xu J; Zhou Q; Tang Q; Storm G; Molema G; Lu PY; Scaria PV; Woodle MC
Nucleic Acids Res; 2004 Nov; 32(19):e149. PubMed ID: 15520458
[TBL] [Abstract][Full Text] [Related]
19. Characterization of polyethylene glycol-grafted polyethylenimine and superparamagnetic iron oxide nanoparticles (PEG-g-PEI-SPION) as an MRI-visible vector for siRNA delivery in gastric cancer in vitro and in vivo.
Chen Y; Lian G; Liao C; Wang W; Zeng L; Qian C; Huang K; Shuai X
J Gastroenterol; 2013 Jul; 48(7):809-21. PubMed ID: 23179610
[TBL] [Abstract][Full Text] [Related]
20. Highly effective antiangiogenesis via magnetic mesoporous silica-based siRNA vehicle targeting the VEGF gene for orthotopic ovarian cancer therapy.
Chen Y; Wang X; Liu T; Zhang DS; Wang Y; Gu H; Di W
Int J Nanomedicine; 2015; 10():2579-94. PubMed ID: 25848273
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]